Aberdeen Group plc Trims Stock Position in ANI Pharmaceuticals, Inc. $ANIP

Aberdeen Group plc decreased its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 26.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 269,678 shares of the specialty pharmaceutical company’s stock after selling 96,255 shares during the quarter. Aberdeen Group plc owned approximately 1.24% of ANI Pharmaceuticals worth $24,703,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of ANIP. GAMMA Investing LLC grew its holdings in ANI Pharmaceuticals by 9.1% in the third quarter. GAMMA Investing LLC now owns 1,505 shares of the specialty pharmaceutical company’s stock valued at $138,000 after purchasing an additional 126 shares during the period. Illinois Municipal Retirement Fund grew its stake in shares of ANI Pharmaceuticals by 1.7% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 8,538 shares of the specialty pharmaceutical company’s stock valued at $782,000 after buying an additional 145 shares during the period. Amalgamated Bank increased its holdings in shares of ANI Pharmaceuticals by 3.1% during the 3rd quarter. Amalgamated Bank now owns 5,066 shares of the specialty pharmaceutical company’s stock worth $464,000 after buying an additional 154 shares during the last quarter. CANADA LIFE ASSURANCE Co raised its position in shares of ANI Pharmaceuticals by 1.0% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock worth $1,267,000 after buying an additional 198 shares during the period. Finally, Hantz Financial Services Inc. raised its position in shares of ANI Pharmaceuticals by 202.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock worth $32,000 after buying an additional 237 shares during the period. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, SVP Krista Davis sold 1,622 shares of the firm’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $82.40, for a total transaction of $133,652.80. Following the completion of the sale, the senior vice president owned 58,564 shares of the company’s stock, valued at approximately $4,825,673.60. This trade represents a 2.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Meredith Cook sold 500 shares of the stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $84.33, for a total transaction of $42,165.00. Following the transaction, the vice president owned 74,374 shares in the company, valued at $6,271,959.42. This trade represents a 0.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 4,322 shares of company stock worth $354,816 in the last three months. 12.70% of the stock is owned by insiders.

Wall Street Analyst Weigh In

ANIP has been the subject of several research analyst reports. Weiss Ratings restated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, December 29th. Barclays assumed coverage on shares of ANI Pharmaceuticals in a report on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 price target on the stock. Guggenheim boosted their price objective on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Finally, Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Six equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $103.43.

ANI Pharmaceuticals Stock Performance

ANI Pharmaceuticals stock opened at $78.90 on Wednesday. ANI Pharmaceuticals, Inc. has a 12-month low of $54.10 and a 12-month high of $99.50. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.58 and a quick ratio of 2.04. The company has a market capitalization of $1.77 billion, a price-to-earnings ratio of 48.40 and a beta of 0.50. The firm’s fifty day moving average price is $81.04 and its 200 day moving average price is $86.36.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.